Cornerstone Wealth Group’s Charles River Laboratories CRL Stock Holding History

Cornerstone Wealth Group’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$203K	Buy	+687	New	+$181K	0.01%	511

Other funds holding CRL

Cooke & Bieler Philadelphia, Pennsylvania $6.36B AUM 0.55% 1-Year Est. Return

Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Confluence Investment Management St. Louis, Missouri $5.97B AUM 5.11% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

J.P. Marvel Investment Advisors Boston, Massachusetts $863M AUM 50.23% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

Cornerstone Wealth Group's CRL Position: Q3 2026 in Review

Cornerstone Wealth Group opened a new position in Charles River Laboratories (CRL) in Q3 2026: 687 shares worth $203K. The stake represents 0.01% of the portfolio and ranks #511 among its holdings.

202 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

Cornerstone Wealth Group held 687 shares of Charles River Laboratories worth $203K as of Q3 2026.
Charles River Laboratories was a new Cornerstone Wealth Group position in Q3 2026.
Charles River Laboratories made up 0.01% of Cornerstone Wealth Group's portfolio in Q3 2026, its #511 holding.
202 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Cornerstone Wealth Group's 13F filing for Q3 2026, filed 2 Nov 2026.